Please use this identifier to cite or link to this item: http://bura.brunel.ac.uk/handle/2438/23849
Full metadata record
DC FieldValueLanguage
dc.contributor.authorIffah, R-
dc.contributor.authorGavins, FNE-
dc.date.accessioned2021-12-30T18:48:42Z-
dc.date.available2021-12-30T18:48:42Z-
dc.date.issued2021-06-14-
dc.identifierORCID iD: Felicity N. E. Gavins https://orcid.org/0000-0001-7008-5423-
dc.identifier.citationIffah, R. and Gavins, F.N.E. (2022) 'Thromboinflammation in coronavirus disease 2019: The clot thickens', British Journal of Pharmacology, 179 (10), pp. 2100 - 2107. doi: 10.1111/bph.15594.en_US
dc.identifier.issn0007-1188-
dc.identifier.urihttps://bura.brunel.ac.uk/handle/2438/23849-
dc.descriptionData availability statement: No data have been shared.-
dc.descriptionLinked articles: This article is part of a themed issue on The second wave: are we any closer to efficacious pharmacotherapy for COVID 19? (BJP 75th Anniversary). To view the other articles in this section visit https://onlinelibrary.wiley.com/doi/10.1111/bph.v179.10/issuetoc-
dc.description.abstractCopyright © 2021 The Authors. Since the start of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, a disease that has become one of the world's greatest global health challenges, the role of the immune system has been at the forefront of scientific studies. The pathophysiology of coronavirus disease 2019 (COVID-19) is complex, which is evident in those at higher risk for poor outcome. Multiple systems contribute to thrombosis and inflammation seen in COVID-19 patients, including neutrophil and platelet activation, and endothelial dysfunction. Understanding how the immune system functions in different patient cohorts (particularly given recent emerging events with the Oxford/AstraZeneca vaccine) is vital to understanding the pathophysiology of this devastating disease and for the subsequent development of novel therapeutic targets and to facilitate possible drug repurposing strategies that could benefit society on a global scale.en_US
dc.description.sponsorshipRoyal Society Wolfson Foundation. Grant Number: RSWF\R3\183001en_US
dc.format.extent2100 - 2107-
dc.format.mediumPrint-Electrlonic-
dc.language.isoen_USen_US
dc.publisherJohn Wiley & Sons Ltd on behalf of British Pharmacological Societyen_US
dc.rightsCopyright © 2021 The Authors. Published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subjectinflammationen_US
dc.subjectneutrophilsen_US
dc.subjectplateletsen_US
dc.subjectresolution pharmacologyen_US
dc.subjectthromboinflammationen_US
dc.subjectthrombosisen_US
dc.titleThromboinflammation in coronavirus disease 2019: The clot thickensen_US
dc.typeArticleen_US
dc.identifier.doihttps://doi.org/10.1111/bph.15594-
dc.relation.isPartOfBritish Journal of Pharmacology-
pubs.issue10-
pubs.publication-statusPublished-
pubs.volume179-
dc.identifier.eissn1476-5381-
dc.rights.holderThe Authors-
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © 2021 The Authors. Published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.3.2 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons